KITCHENER – The Alzheimer Society Waterloo Wellington (ASWW) welcomes the recent announcement by LifeLabs introducing a new portfolio of blood-based biomarker tests to support the early detection and management of Alzheimer’s disease in Ontario.
This development marks a critical step forward in improving access to early screening options for individuals experiencing memory concerns, officials say, especially in community settings where timely diagnosis and intervention are essential.
“Early detection is one of the most powerful tools we have in the fight against Alzheimer’s disease,” said Michelle Martin, CEO of ASWW.
The portfolio includes three tests:
– ApoE test: assesses genetic risk for late-onset Alzheimer’s disease;
– p-tau217 test: a diagnostic biomarker aiding in the detection of Alzheimer’s disease; and
– Beta-Amyloid 42/40 ratio test: detects early markers of the disease, providing a more complete diagnostic picture when used alongside p-tau217.
ASWW officials say they are encouraged by LifeLabs’ collaboration with key healthcare and research partners, including MINT Memory Clinics and the Alzheimer Society of Ontario.
For more information on testing services visit LifeLabs’ website.
